240 related articles for article (PubMed ID: 24332053)
21. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A
Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399
[TBL] [Abstract][Full Text] [Related]
22. [Screening for K-ras mutations in colorectal and lung cancers by using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing].
Zhang HP; Fu L; Chen PQ; Ye YB; Ji TH; Zheng LM
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):757-61. PubMed ID: 21215167
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.
Yu S; Xiao X; Lu J; Qian X; Liu B; Feng J
PLoS One; 2013; 8(7):e68022. PubMed ID: 23874486
[TBL] [Abstract][Full Text] [Related]
24. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Freeman DJ; Juan T; Reiner M; Hecht JR; Meropol NJ; Berlin J; Mitchell E; Sarosi I; Radinsky R; Amado RG
Clin Colorectal Cancer; 2008 May; 7(3):184-90. PubMed ID: 18621636
[TBL] [Abstract][Full Text] [Related]
25. Modified mismatch polymerase chain reaction-restriction fragment length polymorphism detected mutations in codon 12 and 13 of exon 2 of K-
Faleel FD; Zoysa MI; Lokuhetti MD; Gunawardena YI; Chandrasekharan VN; Dassanayake RS
J Cancer Res Ther; 2016; 12(4):1272-1277. PubMed ID: 28169239
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for brain metastases in patients with metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Høgdall E; Poulsen TS; Pfeiffer P; Jensen BV; Yilmaz MK; Christensen IJ; Nielsen D
Acta Oncol; 2017 May; 56(5):639-645. PubMed ID: 28447565
[TBL] [Abstract][Full Text] [Related]
27. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
Udar N; Lofton-Day C; Dong J; Vavrek D; Jung AS; Meier K; Iyer A; Slaughter R; Gutekunst K; Bach BA; Peeters M; Douillard JY
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2001-2010. PubMed ID: 30019318
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer.
Sefrioui D; Sarafan-Vasseur N; Beaussire L; Baretti M; Gangloff A; Blanchard F; Clatot F; Sabourin JC; Sesboüé R; Frebourg T; Michel P; Di Fiore F
Dig Liver Dis; 2015 Oct; 47(10):884-90. PubMed ID: 26160500
[TBL] [Abstract][Full Text] [Related]
29. [Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population].
Cabrera-Mendoza F; Gainza-Lagunes S; Castañeda-Andrade I; Castro-Zárate A
Rev Gastroenterol Mex; 2014; 79(3):166-70. PubMed ID: 25216999
[TBL] [Abstract][Full Text] [Related]
30. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
[TBL] [Abstract][Full Text] [Related]
31. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
[TBL] [Abstract][Full Text] [Related]
32. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.
Dotan E; Meropol NJ; Zhu F; Zambito F; Bove B; Cai KQ; Godwin AK; Golemis EA; Astsaturov I; Cohen SJ
Br J Cancer; 2012 Feb; 106(4):748-55. PubMed ID: 22240781
[TBL] [Abstract][Full Text] [Related]
33. [Standard Chemotherapy with Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer with RAS Mutation].
Yoshimatsu K; Satake M; Sano M; Asaka S; Yamada Y; Okayama S; Yano Y; Yokomizo H; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Sagawa M; Naritaka Y
Gan To Kagaku Ryoho; 2017 Oct; 44(10):918-920. PubMed ID: 29066695
[TBL] [Abstract][Full Text] [Related]
34. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping.
Beau-Faller M; Legrain M; Voegeli AC; Guérin E; Lavaux T; Ruppert AM; Neuville A; Massard G; Wihlm JM; Quoix E; Oudet P; Gaub MP
Br J Cancer; 2009 Mar; 100(6):985-92. PubMed ID: 19293811
[TBL] [Abstract][Full Text] [Related]
35. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
Zeng Q; Xie L; Zhou N; Liu M; Song X
Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
[TBL] [Abstract][Full Text] [Related]
36. High levels of D-dimer correlated with disease status and poor prognosis of inoperable metastatic colorectal cancer patients treated with bevacizumab.
Zhu L; Liu B; Zhao Y; Liu L; Yang C; Yang Y; Zhong H
J Cancer Res Ther; 2014 Dec; 10 Suppl():246-51. PubMed ID: 25693928
[TBL] [Abstract][Full Text] [Related]
37. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
[TBL] [Abstract][Full Text] [Related]
38. Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer.
Geido E; Sciutto A; Rubagotti A; Oliani C; Monaco R; Risio M; Giaretti W
Cytometry; 2002 Aug; 50(4):216-24. PubMed ID: 12210601
[TBL] [Abstract][Full Text] [Related]
39. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?
Selcukbiricik F; Bilici A; Tural D; Erdamar S; Soyluk O; Buyukunal E; Demirelli F; Serdengecti S
Tumour Biol; 2013 Aug; 34(4):2233-9. PubMed ID: 23625655
[TBL] [Abstract][Full Text] [Related]
40. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
